Jump to main content
Jump to site search


ACCURATE QUANTIFICATION OF CARBOPLATIN ADDUCTS WITH SERUM PROTEINS BY MONOLITHIC CHROMATOGRAPHY COUPLED TO ICPMS WITH ISOTOPE DILUTION ANALYSIS

Abstract

This work demonstrates for the first time the potential of monolithic chromatography coupled to double species-specific IDA ICPMS for the detection, and accurate quantification of adducts of plasma/serum proteins with carboplatin, an anti-cancer drug. Results of the Pt fractionation in blood incubated with Pt drugs, to mimic cancer scenarios in real life, suggested that approximately 83% of the Pt in drug-incubated blood is found associated with plasma/serum proteins. Such studies were performed with cisplatin (instead of carboplatin), as cisplatin shows faster kinetics compared to carboplatin and the Pt-DNA adducts have been demonstrated to be the same using both drugs. These results provide first time solid evidence to support that adducts of Pt drugs with plasma proteins are key competitors for the drug binding to DNA in cancer models. The distribution of Pt associated with albumin (HSA), transferrin (Tf) and immunoglobulin (IgG) in human serum was investigated in reconstituted serum samples incubated with clinical concentrations of carboplatin for ten days at 37°C. Two approaches were examined for the separation and detection of the three Pt-proteins adducts. AF4 could not achieve a baseline separation of the three proteins in the real matrix; however, its coupling with ICPMS was found to be particularly useful to provide detailed information on the formation of different adduct isoforms during the optimisation of the conditions for calibrant and spike production (e.g. by incubation of the individual proteins with either, natural or 194Pt-enriched carboplatin). CLC based on one affinity (Protein G) and two weak anion exchange (DEAE) disks coupled to UV-Vis and ICPMS revealed that Pt-HSA adducts represented more than 96% of the protein-bound Pt in serum, whereas Pt-Tf and Pt-IgG represented only about 2% each. Therefore, reference methodology based on the use of double species-specific IDA ICPMS has been developed and validated for the determination of carboplatin-HSA adducts using a simplified separation method with two DEAE monolithic disks. Limits of detection achieved for carboplatin-HSA adducts with this method were 0.005 and 0.003 ng g-1 for 194Pt and 195Pt, respectively. These are about two orders of magnitude lower than those previously reported in the literature. An expanded uncertainty (k=2) of 25 ng g-1 (RSU of 4.7 %) was achieved for a mass fraction of carboplatin-HSA adducts of about 528 ng g-1. The reference methodology developed here will be invaluable for evaluation of dose-dependence response to treatment for individual patients in cancer trials, aimed at finding more effective therapies.

Back to tab navigation

Supplementary files

Publication details

The article was received on 26 Nov 2018, accepted on 31 Jan 2019 and first published on 31 Jan 2019


Article type: Paper
DOI: 10.1039/C8JA00409A
Citation: J. Anal. At. Spectrom., 2019, Accepted Manuscript

  •   Request permissions

    ACCURATE QUANTIFICATION OF CARBOPLATIN ADDUCTS WITH SERUM PROTEINS BY MONOLITHIC CHROMATOGRAPHY COUPLED TO ICPMS WITH ISOTOPE DILUTION ANALYSIS

    R. Larios, M.Estela Del Castillo Busto, D. Garcia-Sar, C. Ward-Deitrich and H. Goenaga-Infante, J. Anal. At. Spectrom., 2019, Accepted Manuscript , DOI: 10.1039/C8JA00409A

Search articles by author

Spotlight

Advertisements